9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors

ConditionAdvanced Solid TumorsEstimated Enrollment: 217Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: BP27772|2011-003394-28Study First Received: December 2, 2011Last Updated: November 1, 2016Estimated Primary Completion Date: April 2018Primary Outcome Measures:Percentage of Participants With Adverse Events|Part 1: Maximum Tolerated Dose (MTD)/Optimal Biological Dose (OBD) of RO5509554 as a Single Agent and in Combination With Paclitaxel|Part 2: Change in Colony Stimulating Factor-1 (CSF-1) Serum Level For Every 2 Weeks (Q2W) Schedule|Part 2: Change in CSF-1 Serum Level For Every 3 Weeks (Q3W) Schedule|Part 2: Change in...

Continue reading

French National Registry of Rare Peritoneal Surface Malignancies

ConditionRare Peritoneal Surface Malignancies|Pseudomyxoma Peritonei|Peritoneal Mesothelioma|Desmoplastic Small Round Cell Tumor|Psammocarcinoma|Primary Peritoneal Serous Carcinoma|Diffuse Peritoneal Leiomyomatosis|Appendiceal Mucinous NeoplasmsEstimated Enrollment: 2171Age Group: Child, Adult, SeniorGender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: CohortStudy ID Numbers: 69HCL16_0406Study First Received: June 30, 2016Last Updated: July 12, 2016Estimated Primary Completion Date: December 2018Primary Outcome Measures:Incidence of rare peritoneal surface malignancies|Impact of specific treatment strategiesSponsors and Collaborators:Hospices Civils de LyonResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02834169...

Continue reading

Gene Therapy for Pleural Malignancies

ConditionPleural Mesothelioma|Metastatic Pleural EffusionsEstimated Enrollment: 18Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: 803776|P01CA066726Study First Received: March 3, 2006Last Updated: February 21, 2017Estimated Primary Completion Date: April 2023Primary Outcome Measures:To determine toxicity of two doses of intrapleural BG00001 (Ad.hIFN-β over 8 days, and|To assess systemic and intrapleural cytokine responses as well as cellular and humoral immune responses after repeated BG00001 instillation,|and to assess, in a preliminary way, efficacy via tumor regression, time to progression and survival.Sponsors and Collaborators:University of Pennsylvania|National Cancer Institute...

Continue reading

CART-meso in Mesothelin Expressing Cancers

ConditionMetastatic Pancreatic (Ductal) Adenocarcinoma|Epithelial Ovarian Cancer|Malignant Epithelial Pleural MesotheliomaEstimated Enrollment: 19Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: UPCC31213Study First Received: June 6, 2014Last Updated: March 16, 2017Estimated Primary Completion Date: November 2015Primary Outcome Measures:Number of Adverse EventsSponsors and Collaborators:University of PennsylvaniaResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02159716...

Continue reading

Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin

ConditionMalignant Pleural Mesothelioma|Nonsquamous Nonsmall Cell Neoplasm of LungEstimated Enrollment: 31Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: ONC-2011-001Study First Received: May 24, 2013Last Updated: February 9, 2017Estimated Primary Completion Date: May 2016Primary Outcome Measures:To determine the dose limiting toxicities (DLTs) of Tivantinib|To determine the pharmacokinetics profile of Tivantinib in combination with Carboplatin and Pemetrexed|To assess the preliminary anti-tumor activity of Tivantinib with PFS|To assess the preliminary anti-tumor activity of Tivantinib with RECIST|To evaluate dynamic changes in blood levels|To evaluate the expression of biomarkers|To...

Continue reading

Autologous Redirected RNA Meso-CIR T Cells

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 18Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: UPCC 17510Study First Received: May 17, 2011Last Updated: October 18, 2016Estimated Primary Completion Date: July 2015Primary Outcome Measures:Adverse Events|Clinical response RateSponsors and Collaborators:University of PennsylvaniaResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01355965...

Continue reading

Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)

ConditionLung Cancer|MesotheliomaEstimated Enrollment: 22Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 2010-0057|NCI-2011-02080Study First Received: May 27, 2010Last Updated: November 9, 2016Estimated Primary Completion Date: May 2018Primary Outcome Measures:Maximum Tolerated Dose (MTD) of IMRT after radical pleurectomy/decortication (PD)Sponsors and Collaborators:M.D. Anderson Cancer CenterResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01134146...

Continue reading

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

ConditionLung CancerEstimated Enrollment: 18Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: 12-169Study First Received: January 9, 2013Last Updated: January 27, 2017Estimated Primary Completion Date: January 2018Primary Outcome Measures:Maximum Tolerated Dose (MTD)|safety|detection of virus in body fluids|evaluation of viral appearance in tumor|Therapeutic efficacySponsors and Collaborators:Memorial Sloan Kettering Cancer Center|Genelux CorporationResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01766739...

Continue reading

Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 60Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: TreatmentStudy ID Numbers: 2011-0289|HRPO Log Number A-15872|NCI-2010-02375|W81XWH-10-1-0699Study First Received: June 27, 2013Last Updated: October 6, 2016Estimated Primary Completion Date: December 2018Primary Outcome Measures:1-Year Progression Free SurvivalSponsors and Collaborators:M.D. Anderson Cancer Center|U.S. Army Medical Research and Materiel Command|Memorial Sloan Kettering Cancer Center|Sellas Life Sciences GroupResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01890980...

Continue reading

Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 150Age Group: Child, Adult, SeniorGender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Case-Only|Time Perspective: RetrospectiveStudy ID Numbers: ONC/OSS-02/2012Study First Received: May 27, 2013Last Updated: February 9, 2017Estimated Primary Completion Date: December 2016Primary Outcome Measures:Expression of TUBB3 and BRCA1 in MPM tumor tissue by immunohistochemistry and RT-PCR.|Association of expression of TUBB3 and BRCA1 with clinical outcome (response, survival) .Sponsors and Collaborators:Armando Santoro, MD|Istituto Clinico HumanitasResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01865045...

Continue reading